- Home
- VINP vs PCRX Comparison
VINP vs PCRX Comparison
Compare VINP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- PCRX
- Stock Information
- Founded
- VINP 2009
- PCRX 2006
- Country
- VINP Brazil
- PCRX United States
- Employees
- VINP N/A
- PCRX N/A
- Industry
- VINP Investment Managers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- PCRX Health Care
- Exchange
- VINP Nasdaq
- PCRX Nasdaq
- Market Cap
- VINP 641.7M
- PCRX 1.2B
- IPO Year
- VINP 2021
- PCRX 2011
- Fundamental
- Price
- VINP $10.35
- PCRX $26.09
- Analyst Decision
- VINP Strong Buy
- PCRX Buy
- Analyst Count
- VINP 2
- PCRX 10
- Target Price
- VINP $13.50
- PCRX $29.30
- AVG Volume (30 Days)
- VINP 62.7K
- PCRX 892.8K
- Earning Date
- VINP 02-26-2025
- PCRX 02-27-2025
- Dividend Yield
- VINP 6.75%
- PCRX N/A
- EPS Growth
- VINP N/A
- PCRX N/A
- EPS
- VINP 0.60
- PCRX N/A
- Revenue
- VINP $88,217,697.00
- PCRX $694,957,000.00
- Revenue This Year
- VINP $17.23
- PCRX $5.14
- Revenue Next Year
- VINP $51.06
- PCRX $2.44
- P/E Ratio
- VINP $17.33
- PCRX N/A
- Revenue Growth
- VINP 9.03
- PCRX 4.40
- 52 Week Low
- VINP $9.01
- PCRX $11.16
- 52 Week High
- VINP $11.85
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- VINP 56.01
- PCRX 77.75
- Support Level
- VINP $10.00
- PCRX $25.06
- Resistance Level
- VINP $10.49
- PCRX $27.10
- Average True Range (ATR)
- VINP 0.22
- PCRX 1.45
- MACD
- VINP 0.07
- PCRX 0.28
- Stochastic Oscillator
- VINP 72.73
- PCRX 86.23
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.